Macular dysfunction is a common vision issue associated with aging – but often, it’s not detected until it’s somewhat advanced. Pennsylvania startup Maculogix has developed a device that can detects vision impairment associated with age-related macular degeneration, retinitis pigmentosa and other macular diseases before individuals actually notice symptoms – helping doctors intervene earlier with this condition.
Maculogix just raised $5 million, according to a regulatory filing. It’s got a diagnostic tool on the market that detects age-related macular degeneration, retinitis pigmentosa and other macular diseases. The device has had 510(k) clearance from the Food and Drug Administration.
It works by measuring dark adaption function – which is the way the eye recovers vision when going from daylight to darkness. Because dark adaption function is impaired when a patient has even early AMD and retinitis pigmentosa, the company finds it a useful metric to track when monitoring disease progression.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
It works in a similar manner to a cardiac stress test. When measuring heart function, patients are studied after the stress of walking on a treadmill. With the AdaptDx test, the company says it measures how the eye recovers after the stress of a mild photobleach.
The devicemaker has raised about $11.5 million since 2011, according to SEC filings. It hasn’t yet returned calls from MedCity News about the specific use of its funding – though one would wager it’s to further market the already-approved device.